Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Breast cancer methylomes establish an epigenomic foundation for metastasis.

Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA.

Sci Transl Med. 2011 Mar 23;3(75):75ra25. doi: 10.1126/scitranslmed.3001875.

2.

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA.

Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.

3.

DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.

Roll JD, Rivenbark AG, Jones WD, Coleman WB.

Mol Cancer. 2008 Jan 25;7:15. doi: 10.1186/1476-4598-7-15.

4.

Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype.

Moarii M, Reyal F, Vert JP.

Hum Genomics. 2015 Oct 13;9:26. doi: 10.1186/s40246-015-0048-9.

5.

A seven-gene CpG-island methylation panel predicts breast cancer progression.

Li Y, Melnikov AA, Levenson V, Guerra E, Simeone P, Alberti S, Deng Y.

BMC Cancer. 2015 May 19;15:417. doi: 10.1186/s12885-015-1412-9.

6.

CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.

Jing F, Yuping W, Yong C, Jie L, Jun L, Xuanbing T, Lihua H.

Tumour Biol. 2010 Aug;31(4):321-31. doi: 10.1007/s13277-010-0040-x. Epub 2010 May 20.

PMID:
20490964
7.

Unique DNA methylome profiles in CpG island methylator phenotype colon cancers.

Xu Y, Hu B, Choi AJ, Gopalan B, Lee BH, Kalady MF, Church JM, Ting AH.

Genome Res. 2012 Feb;22(2):283-91. doi: 10.1101/gr.122788.111. Epub 2011 Oct 11.

8.

Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?

Bae JM, Rhee YY, Kim KJ, Wen X, Song YS, Cho NY, Kim JH, Kang GH.

Hum Pathol. 2016 Jan;47(1):85-94. doi: 10.1016/j.humpath.2015.09.008. Epub 2015 Sep 25.

PMID:
26520418
9.

High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer.

Chen HY, Zhu BH, Zhang CH, Yang DJ, Peng JJ, Chen JH, Liu FK, He YL.

Cancer Sci. 2012 Jan;103(1):73-9. doi: 10.1111/j.1349-7006.2011.02129.x. Epub 2011 Nov 24.

10.

The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.

Karpinski P, Ramsey D, Grzebieniak Z, Sasiadek MM, Blin N.

Mol Cancer Res. 2008 Apr;6(4):585-91. doi: 10.1158/1541-7786.MCR-07-2158.

11.

Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.

Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka F, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, Suzuki H, Ueda M, Kondo Y.

Cancer Prev Res (Phila). 2015 Aug;8(8):702-11. doi: 10.1158/1940-6207.CAPR-14-0306. Epub 2015 Jun 10.

12.

Genome-scale analysis of aberrant DNA methylation in colorectal cancer.

Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA, Laird PW.

Genome Res. 2012 Feb;22(2):271-82. doi: 10.1101/gr.117523.110. Epub 2011 Jun 9.

13.

CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.

Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S.

Mod Pathol. 2008 Mar;21(3):245-55. doi: 10.1038/modpathol.3800982. Epub 2008 Jan 18.

14.

CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.

Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH.

Arch Pathol Lab Med. 2008 Oct;132(10):1657-65. doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.

PMID:
18834226
15.

Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma.

An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63.

16.

CpG island methylator phenotype predicts progression of malignant melanoma.

Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS.

Clin Cancer Res. 2009 Mar 1;15(5):1801-7. doi: 10.1158/1078-0432.CCR-08-1361. Epub 2009 Feb 17.

17.

Biological significance of the CpG island methylator phenotype.

Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M.

Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):35-42. doi: 10.1016/j.bbrc.2014.07.007. Epub 2014 Jul 10. Review.

PMID:
25016183
18.

The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.

Ferracin M, GafĂ  R, Miotto E, Veronese A, Pultrone C, Sabbioni S, Lanza G, Negrini M.

J Pathol. 2008 Apr;214(5):594-602. doi: 10.1002/path.2318.

PMID:
18241079
19.

CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma.

Li B, Liu W, Wang L, Li M, Wang J, Huang L, Huang P, Yuan Y.

Ann Surg Oncol. 2010 Jul;17(7):1917-26. doi: 10.1245/s10434-010-0921-7. Epub 2010 Jan 29.

PMID:
20112070
20.

CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression.

Zhao X, Yang F, Li S, Liu M, Ying S, Jia X, Wang X.

Br J Haematol. 2014 Jun;165(5):649-58. doi: 10.1111/bjh.12811. Epub 2014 Mar 6.

PMID:
24601943

Supplemental Content

Support Center